No one, and I mean no one has covered the Walgreens Rite Aid Corporation (NYSE:RAD) merger in more detail than BNL Finance. We have said from the get go that RAD stock is the perfect merger arbitrage play, and upped that stance when RAD started to fall a few months back.
Now that Fred's is acquiring more than the necessary RAD stores to complete the merger, there is no question investors should buy RAD for a merger arbitrage gain to the upside. It is safe like cash, but will perform better than stocks. Once the merger completes, we suggest putting RAD stock profits in WBA. (read here)
ACADIA Pharmaceuticals (NASDAQ:ACAD) finished with stock gains of 15% after Phase 2 Nuplazid data was statistically significant in ADP. This was a highly anticipated trial, and if not for some concerns with the data, ACAD might very well be at new highs right now.Still, we saw the data as encouraging, suggesting a successful Phase 3 trial. More importantly, we think the data has bigger implications for Nuplazid sales in off label markets and with acquirers. At the very least, ACAD likely sured up its place with a big marketing partner to help accelerate Nuplazid sales moving forward (read here)
The odds are stacked against Fitbit Inc (NYSE:FIT), and rightfully so. Fact is this is a company we have been highly critical of for choosing not to launch a smart wearable ahead of the holiday season, nor realizing that what Wall Street wants is for Fitbit to create a recurring revenue stream.
Still, data from IDC shows how Fitbit's success and the wearables market go hand-in-hand. The questions of survival are no longer relevant, and so long Fitbit decides to launch a new smart wearable in the first half of 2017, investors will see first hand the significant consumer demand. This time around, we think Wall Street will notice, and Fitbit stock becomes one of the best turnaround stories of 2017. (read here)